PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Latest Episodes:

Miguel Regueiro, MD - Taking Fuel From the IBD Fire: Applying New Evidence on Sphingosine-1-Phosphate Receptor Modulation as an Effective Oral Option for Management of Ulcerative Colitis Jun 01, 2023

Show notes

Go online to PeerView.com/FNG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Much progress has been made in defining the genetic abnormalities and associated abnormal pathophysiology underlying the spontaneous and chronic inflammation that characterizes inflammatory bowel disease (IBD). Medications that suppress or modify immune activity form the core of effective treatment for IBD. Sphingosine-1-phosphate (S1P) receptor modulators, a small-molecule therapeutic option, provide a target-specific approach with a favorable safety profile. Multiple S1P receptor modulators are in development, and ozanimod became the first agent in this class to receive FDA approval for the treatment of moderately to severely active ulcerative colitis in 2021. In this activity, based on a recent live symposium, expert faculty will discuss the therapeutic effects of S1P receptor modulators on the underlying pathophysiology of IBD and identify patients with UC who could benefit from treatment with these agents. In addition, the faculty will discuss individualizing treatment using S1P receptor modulators for appropriate patients with IBD in accordance with current evidence and guidelines. Upon completion of this activity, participants should be better able to: Explain how the therapeutic effects of sphingosine-1-phosphate (S1P) receptor modulators address the underlying pathophysiology of IBD; Identify patients with UC who could benefit from the use of therapy with S1P receptor modulators; and Individualize treatment using S1P receptor modulators for appropriate patients with UC in accordance with current evidence and guidelines

Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF - Addressing Unmet Nursing Needs in the Management of IBS-C: Understanding the Mechanism of Disease, Newer Therapies, and Coordinated Approaches to Treatment Barriers Jun 01, 2023

Show notes

Go online to PeerView.com/RZN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with irritable bowel syndrome with constipation (IBS-C) are often more comfortable discussing their concerns with the nurses on their healthcare team, which demonstrates the need for team-based care in order to maximize management, enhance outcomes, and improve quality of life. This activity features an expert overview of the pathophysiology of IBS-C and targets for therapy, including novel NHE3 inhibitors, as well as evidence-based treatment approaches with a focus on identifying and overcoming barriers to guideline-based care. Hear about recent advances in the diagnosis and treatment of IBS-C, specifically the mechanisms of the condition, current and emerging therapies, and coordinated approaches for overcoming barriers to care. Upon completion of this activity, participants should be better able to: Describe the pathophysiology and potential therapeutic targets for IBS-C; Use patient-centered tactics and tools to overcome barriers to guideline-directed IBS-C management; and Create team-based approaches to IBS-C management in accordance with current evidence and guidelines, recognizing the appropriate use of current and emerging therapeutic agents

Anna Chodos, MD, MPH - Facilitating Cognitive Assessment in Primary Care for the Timely Detection of Alzheimer’s Disease: Leveraging Medicare Reimbursement Mechanisms to Improve Clinical Care Jun 01, 2023

Show notes

Go online to PeerView.com/XUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The timely detection and diagnosis of Alzheimer’s disease (AD) can provide patients with numerous opportunities—earlier treatment initiation, increased eligibility for clinical trials, participation in long-term care planning, and the chance to make lifestyle changes to slow cognitive decline. In this activity, based on a recent live symposium, experts discuss practical strategies for integrating cognitive screening into routine care visits and conducting more detailed cognitive evaluations that results in a written care plan with patients who fail a brief cognitive screening assessment. Experts also share guidance on working with Medicare reimbursement mechanisms to facilitate consistent and effective use of early detection tools and practical skills to counsel patients and their caregivers before, during, and after the diagnostic process. Upon completion of this activity, participants should be better able to: Integrate routine cognitive assessment in outpatient visits of older adults who present with signs and symptoms of cognitive impairment to facilitate the timely diagnosis of MCI and mild dementia due to AD; Employ appropriate tools for documentation and coding of procedures (eg, cognitive assessments) and services for patients presenting with cognitive symptoms or concerns; and Implement effective communication strategies to educate patients and caregivers about the clinical significance and prognostic implications of their cognitive assessment results

Nicholas K. Mollanazar, MD, MBA - Targeting Disease Pathophysiology to Achieve Effective Treatment in Prurigo Nodularis Jun 01, 2023

Show notes

Go online to PeerView.com/AMT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you know about prurigo nodularis (PN)? Test yourself in this interactive question-based activity that customizes to meet your learning needs. Throughout the activity, an expert dermatologist will review the latest evidence for current and emerging treatment strategies and discuss the necessary tools to effectively navigate care for patients with PN. Don’t forget to check your learning plan summary for customized feedback! Upon completion of this activity, participants should be better able to: Characterize the burden of disease and unmet needs associated with PN; Discuss how increased insight into PN pathophysiology is being applied in the development of novel therapeutic strategies; and Develop evidence-based, individualized treatment plans for patients with PN, incorporating new and emerging treatment options as appropriate

Monica Tang, MD - Pulling the Plug on Severe Asthma: Taking a Closer Look at an Underrecognized Biomarker to Assess Disease Severity and Tailor Treatment Jun 01, 2023

Show notes

Go online to PeerView.com/SGZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mucus plugging contributes to airway obstruction and death in acute asthma and is increasingly being recognized as a significant contributory factor to persistent, severe asthma. Pulmonologists, allergy and immunology specialists, and other healthcare professionals need to be aware of these latest insights into the pathophysiology of severe asthma to optimally care for their patients. Through a collection of short, focused educational modules, this PeerView activity allows learners to combine self-assessment with concise clinical content in an interactive format. Dr. Monica Tang will show learners how to identify the presence of airway mucus plugging on HRCT, and she will review the latest evidence with regard to mucus plugging treatment. Upon completion of this activity, participants should be better able to: Explain the role of mucus plugging as a contributory factor to airway obstruction and symptoms in severe asthma and its implications for treatment; Identify the presence of airway mucus plugging on HRCT according to current expert recommendations; and Apply recent insights into the role of mucus plugging, as well as the latest clinical evidence, to the selection of treatment for patients with severe asthma

Hyman Scott, MD, MPH, David Alain Wohl, MD - Exchanging PrEP Insights: Clinical Expert and Patient Perspectives on How to Become a Trusted HIV Prevention–Certified Provider Apr 26, 2023

Show notes

Go online to PeerView.com/XFA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in HIV prevention and a patient advocate discuss the benefits of pre-exposure prophylaxis (PrEP) and the necessary tools for engaging patients in conversations about sexual health practices as well as strategies for improving the uptake of HIV prevention measures. Upon completion of this activity, participants should be better able to: Effectively engage clients in conversations about sexual health practices to assess HIV risk factors and support their ability to have healthy sex lives; Apply current evidence with individual client needs/preferences when integrating HIV prevention options (eg, PrEP, PEP, viral suppression, female condoms) into practice; Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among clients at increased risk for HIV infection; and Describe currently available and emerging tools that have been shown to significantly reduce the risk of HIV transmission or acquisition.

Saira Z. Sheikh, MD, FAAAAI, FACAAI, FACR, Brad Rovin, MD, FASN, FACP - Improving the Patient Experience in SLE and LN: The Intersection of Early Diagnosis, Individualized Treatment, and Culturally Competent Care Apr 13, 2023

Show notes

Go online to PeerView.com/JPU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Observed differences in healthcare disparities for patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) have led to the recognition of racial and ethnic minorities as an independent predictor of worse disease outcomes in SLE/LN. Earlier diagnosis, earlier intervention, treatment strategies targeted to clinical remission or low disease activity, and effective communication and collaboration between providers and patients could offer the opportunity to reduce damage, thus improving long-term outcomes. Through a collection of short, focused educational modules, this PeerView activity allows learners to combine self-assessment with concise clinical content in an interactive format. Drs. Sheikh and Rovin will explore the emerging concept of treat to target, as well as the use of currently available and new/emerging biologic therapies, along with strategies to help learners optimize treatment for patients with SLE/LN. Upon completion of this activity, participants should be better able to: Diagnose SLE, including LN, as early as possible in the course of disease to prevent organ damage and initiate appropriate therapy; Monitor disease activity and response to treatment in SLE and LN based on individual patient needs; Select appropriate treatment for SLE and LN to reduce disease activity, prevent organ damage, minimize drug toxicity, and improve quality of life; and Deliver patient-centered and culturally competent care to improve management of symptoms and promote adherence to long-term treatment in patients with SLE and LN.

Paul Kwo, MD, AGAF, FACG, FAASLD - HBV Is Primary! Your Role in the "Call to Action" to Eliminate Viral Hepatitis By 2030 Apr 06, 2023

Show notes

Go online to PeerView.com/AYK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hepatology discusses the importance of early detection of hepatitis B virus (HBV) infection and presents current and evolving screening, vaccination, and treatment guidelines. The expert emphasizes the role of primary care providers in managing patients with chronic HBV and in helping to reach the WHO goal of eliminating viral hepatitis as a public health threat by 2030 through vaccination, screening, and patient education. Finally, the expert clarifies when patients with chronic HBV infection should be referred for specialty care. Upon completion of this activity, participants should be better able to: Describe the burden and consequences of HBV infection and how chronic HBV can lead to end-stage liver disease and hepatocellular carcinoma; Identify patients who should be screened for HBV, which tests should be ordered, and how to interpret the results; Manage HBV in the primary care setting in accordance with current evidence and guidelines, recognizing patients who require specialty care referral; and Implement patient-centered and culturally relevant strategies to promote adherence to HBV treatment and retention in care.

Robert C. Green, MD, MPH - Revisiting the Role of Genetic Testing in Patients at Risk for Late-Onset Alzheimer’s Disease: How Will the Latest Evidence and Evolving Management Paradigm Impact Treatment Decisions for Your Patients? Apr 06, 2023

Show notes

Go online to PeerView.com/AQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Late-onset Alzheimer’s disease (LOAD) has a substantial genetic component, with heritability estimated to be between 40% and 80%, and the APOE ε4 allele is the strongest individual genetic risk factor for LOAD. Until recently, the APOE genotype test has been primarily used as a research tool and not recommended for clinical use. However, with the recent advances in disease-modifying therapies (DMTs), including several anti–amyloid monoclonal antibodies approved or in late-stage development, it is more important to determine which patients have the APOE ε4 allele and whether these patients are at an elevated risk of developing amyloid-related imaging abnormalities (ARIA). In this activity, based on a recent live webcast, experts examine the significance of APOE ε4 carrier status on the risk for developing LOAD, as well as the potential implications for patient care, including the increased risk for ARIA in patients taking anti-amyloid monoclonal antibodies. They provide guidance on identifying patients who may be candidates for genetic risk testing and share their best practices for interpreting and disclosing APOE test results and providing appropriate genetic counseling to patients and their families. Upon completion of this activity, participants should be better able to: Recognize the significance of APOE ε4 carrier status on the risk for late-onset Alzheimer's disease (LOAD) and the potential implications for patient care; Identify patients who may be candidates for genetic risk testing, and provide guidance on the benefits and limitations of direct-to-consumer testing versus genetic testing that is performed in a healthcare setting; and Interpret and share genetic risk test results with patients and their families in a clear, understandable manner, and tailor genetic counseling services to individual patients’ needs in consultation with other members of the healthcare team.

Neal K. Lakdawala, MD, Anjali Tiku Owens, MD - Loosening the Grip of Hypertrophic Cardiomyopathy: Updated Strategies for Timely Diagnosis and Disease-Modifying Treatment Apr 06, 2023

Show notes

Go online to PeerView.com/GYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and has a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. The FDA has recently approved a noninvasive, first-in-class cardiac myosin inhibitor specifically indicated for the treatment of HCM—meaning timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment. In this activity, based on a recent live symposium, expert panelists present practical skills and guidance to accurately diagnose HCM and apply recent treatment advances to patients with various clinical presentations of HCM. They begin by sharing the rationale for maintaining a high index of suspicion for HCM and review diagnostic strategies. The Clinical Consults portion of this activity features case examples to demonstrate current practices in diagnosis and offer practical guidance for treating patients—focusing on personalized care with new and emerging therapeutic options. Concluding with an engaging Q&A, this activity is for anyone involved in the care of patients with HCM interested in loosening the grip of this increasingly treatable disease. Upon completion of this activity, participants should be better able to: Suspect the presence of HCM based on clinical symptoms, pathologic features, and/or family history; Differentially diagnose patients suspected of having HCM consistent with current guidance to promote early diagnosis and timely treatment; and Individualize treatment for patients with HCM based on the efficacy, safety, and potential ability of the therapeutic strategy to address the underlying disease pathophysiology.